Key Takeaways:
Immix Biopharma Inc. (IMMX) reported a 95% complete response rate in its Phase 2 trial for NXC-201, a CAR-T therapy for relapsed/refractory AL amyloidosis, a rare disease that causes organ failure. The results from the first 20 patients in the NEXICART-2 study represent a significant step forward in treating the difficult-to-manage condition.
“As a potential frontline therapy in AL Amyloidosis, we believe there’s potential to transform a usual 2-year treatment, into a one-and-done: NXC-201,” Gabriel Morris, President and Chief Financial Officer of Immix Biopharma, said in a statement.
The interim data showed 19 of 20 heavily pretreated patients, who had received a median of four prior lines of therapy, achieved a complete response (CR). All four patients who were previously minimal residual disease (MRD) negative, a measure of deep remission, converted to a full CR. All complete responses were achieved within one year of dosing, and no patients who achieved CR have relapsed to date.
The results position NXC-201 as a potentially transformative treatment for AL amyloidosis, where toxic light chains produced by the immune system damage the heart, kidney, and liver. The market for amyloidosis treatments was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025, according to Grand View Research. Based on the strong results, ImmixBio plans to initiate a multi-center, randomized Phase 3 trial for newly diagnosed patients and expects the next data update in late September 2026.
NXC-201 is a CAR-T cell therapy that targets B-cell maturation antigen (BCMA) to eliminate the source of the toxic proteins. This approach teaches the patient's own immune system to fight the disease. The therapy has already received Breakthrough Therapy, RMAT, and Orphan Drug designations from the U.S. Food and Drug Administration, highlighting its potential to address a significant unmet need.
The company is now focused on the path to commercialization. Management stated that it expects to present 1-year follow-up data from the 45-patient study by the end of March 2027, which it believes will be sufficient to support a Biologics License Application (BLA) submission to the FDA. Analyst price targets for IMMX have a median of $20, reflecting optimism about the drug's prospects.
This article is for informational purposes only and does not constitute investment advice.
